ST. LOUIS -- (BUSINESS WIRE) -- PierianDx announced today that Moffitt Cancer Center in Tampa, FL and Fletcher Allen Health Care in Burlington, VT and affiliated with the University of Vermont College of Medicine, have signed customer contracts to join the network of partners using PierianDx’s genetic software services.
PierianDx offers an end-to-end informatics solution for efficiently managing next-generation sequencing processes and sharing clinical insights across a partner network. PierianDx has a license agreement with Washington University in St. Louis where the software tools were developed and continue to be used for clinical practice and research initiatives.
“Being able to better analyze DNA and genetic markers through PierianDx’s products will help us improve our patient-centered care, including diagnosis and treatment,” said Anthony Magliocco, M.D., Department Chair of Pathology at Moffitt. “Through sharing clinical interpretations, we expect to gain meaningful insights that could lead to better patient outcomes.”
Unlike other genetic testing tool start-ups, PierianDx:
1) offers a tool and process that’s been in clinical use at a leading
academic hospital for several years
2) provides an integrated solution to next-generation sequencing, enabling a more rapid diagnosis and individualized treatments
3) shares data, allowing its knowledge base to grow, ultimately improving the quality of clinical interpretations with every patient case.
Ted Briscoe, Chief Executive Officer of PierianDx, said, “We are happy to provide these leading institutions with our key bioinformatics tools, cloud storage and a seamless service for managing their next-generation sequencing processes. We are also helping their labs with assay validation to help facilitate offering new clinical services to their patients.”
PierianDx enables clinical labs to deliver patient-specific diagnosis and treatments based on an individual’s DNA. In active use since 2011 by Washington University in St. Louis, PierianDx’s proprietary Clinical Genomicist Workstation software, knowledge bases, IT backbone and workflow management tools provide an end-to-end solution for managing clinical next-generation sequencing processes. For more information, please visit www.pieriandx.com or @PierianDx on Twitter.
About Moffitt Cancer Center
Located in Tampa, Moffitt is one of only 41 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s excellence in research, its contributions to clinical trials, prevention and cancer control. Moffitt is the No. 1 cancer hospital in Florida and has been listed in U.S. News & World Report as one of their “Best Hospitals” for cancer since 1999. With more than 4,200 employees, Moffitt has an economic impact on the state of nearly $2 billion. For more information, visit MOFFITT.org, and follow the Moffitt momentum on Facebook, Twitter and YouTube.
About Fletcher Allen Health Care
Fletcher Allen Health Care, together with our partners at the University of Vermont College of Medicine and the College of Nursing and Health Sciences, is Vermont’s academic medical center. Fletcher Allen, along with Central Vermont Medical Center, CVPH Medical Center and Elizabethtown Community Hospital, are members of Fletcher Allen Partners, established to develop a more coordinated system of care throughout the region. Fletcher Allen also serves as a regional referral center -- providing advanced care to approximately one million people in Vermont and northern New York -- and as a community hospital for approximately 150,000 residents in Chittenden and Grand Isle counties. For more information about Fletcher Allen, find us online at www.fletcherallen.org or on our Facebook, Twitter, YouTube, and blog sites at www.fletcherallen.org/socialmedia.